Valfix Adverse Reactions

100 mg: The most common adverse events reported are malaise and fatigue, respiratory tract infections, headache, abdominal discomfort and pain, nausea, vomiting and diarrhoea.
Hepatobiliary disorders: Elevation of ALT.
Musculoskeletal, connective tissue and bone disorders: Elevation of CPK, muscle disorders, including myalgia and cramps.
Blood and lymphatic system disorders: Thrombocytopenia.
In patients with HIV infection, cases of pancreatitis and peripheral neuropathy (or paresthesia) have been reported, although no relationship to treatment with lamivudine has been clearly established.
Cases of lactic acidosis, usually associated with severe hepatomegaly and hepatic steatosis, have been reported with the use of nucleoside analogue combination therapy in patients with HIV. There have been occasional reports of these adverse events in hepatitis B patients with decompensated liver disease.
150 mg: The most common adverse events reported are hyperlactataemia, headache, nausea, vomiting, upper abdominal pain, diarrhoea, rash, alopecia, arthralgia, muscle disorders, fatigue, malaise and fever.
Weight and levels of blood lipids and glucose may increase during antiretroviral therapy.
In HIV-infected patients with severe immune deficiency at the time of initiation of combination antiretroviral therapy (CART), an inflammatory reaction to asymptomatic or residual opportunistic infections may arise. Autoimmune disorders (such as Graves' disease) have also been reported to occur in the setting of immune reactivation; however, the reported time to onset is more variable and these events can occur many months after initiation of treatment.
Cases of osteonecrosis have been reported, particularly in patients with generally acknowledged risk factors, advanced HIV disease or long-term combined antiretroviral exposure (CART). The frequency of which is unknown.